ArticleNpj mental health research2026
A scoping review: ketamine or esketamine when used to assist psychotherapy or in combination with psychotherapy for the management of depression in adults.
Article in Npj mental health research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This scoping review maps literature for use of ketamine or esketamine with psychotherapy for depression or depressive symptoms. Forty-seven studies were identified including 4/47 (9%) randomized controlled trials, 4/47 (9%) open label trials, 27/47 (57%) observational or retrospective studies, and 12/47 (26%) individual case reports. Studies were categorized as Ketamine/Esketamine Combined with Psychotherapy (KCP/ES-KCP), where an altered state is not necessary for psychotherapy, or Ketamine/Esketamine Assisted Psychotherapy (KAP/ES-KAP), where an altered state and/or integration of the experience is central to the psychotherapy. The 47 included 23/47(49%) KAP, 1/47 (2%) ES-KAP, 7/47 (15%) KCP, 3/47 (6%) ES-KCP, 8/47 (17%) dual KAP/KCP and 1/47 (2%) dual ES-KAP/ES-KCP. Four studies could not be categorized. Separation into these categories was useful to more clearly report current state of the literature. Though previous reviews have suggested KAP is of benefit for depression, KAP studies were limited by lack of RCTs, lack of comparison groups without psychotherapy, and a large number of individual case reports. To date, fewer studies, but higher quality data support a KCP model, with 3 studies suggesting benefit to combining ketamine with cognitive behavioral therapy (CBT). Further, high quality research including accurate reporting and description of psychotherapy model is required.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.